Research programme: skin disorder therapeutics - RXi Pharmaceuticals/TransDerm

Drug Profile

Research programme: skin disorder therapeutics - RXi Pharmaceuticals/TransDerm

Latest Information Update: 05 May 2016

Price : $50

At a glance

  • Originator RXi Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Skin disorders

Most Recent Events

  • 02 May 2016 RXi Pharmaceuticals has patent protection for sd-rxRNA® platform in Europe
  • 09 Jun 2015 RXi Pharmaceuticals receives patent allowance for rxRNAori® in USA
  • 30 Jun 2014 No development reported for Skin disorders in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top